Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung

Acta Med Okayama. 2006 Oct;60(5):295-8. doi: 10.18926/AMO/30737.

Abstract

A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first case developing fatal paclitaxel-induced pulmonary toxicity to date. Interstitial pneumonia should be considered one of the possible life-threatening complications during treatment with paclitaxel.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Aged
  • Anti-Inflammatory Agents / therapeutic use
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Fatal Outcome
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / diagnosis
  • Lung Diseases, Interstitial / drug therapy
  • Lung Diseases, Interstitial / pathology
  • Lung Neoplasms / drug therapy*
  • Male
  • Methylprednisolone / therapeutic use
  • Paclitaxel / adverse effects*
  • Paclitaxel / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents, Phytogenic
  • Paclitaxel
  • Methylprednisolone